OmniAb, Inc.

OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights https://lnkd.in/gcR35VRU

OmniAb is at World ADC London this week to see how we can best leverage our discovery platform for the latest trends in ADC design and preclinical development. Meet us at booth 19 and join our talk tomorrow to learn how OmniAb can accelerate your ADC discovery. See you there! https://lnkd.in/gw9Y5jxZ #WorldADC

OmniAb to Report Fourth Quarter 2024 Financial Results on March 18 https://lnkd.in/gErREmJy

OmniAb was thrilled to attend UC Berkeley's Evening with Industry, hosted by ACS@Berkeley. We had a great time interacting with bright students who were excited to learn more about the industry, internship opportunities and career pathways. Thank you for including us in this wonderful event!

Congratulations to OmniAb Board Member Jennifer Cochran, PhD who has been elected to the National Academy of Engineering! Dr. Cochran joins the nation’s most knowledgeable engineering experts as she is recognized for her scientific leadership and biotechnology entrepreneurship. Congratulations to Dr. Cochran and the newly elected members of the NAE Class of 2025! #NAE2025 https://lnkd.in/gbTTCxry?

A recently published paper provides preclinical results for JNJ-78306358, a bispecific T cell-engaging antibody targeting CD3 and HLA-G. The antibody was derived from OmniAb, Inc.'s OmniRat (OMT?) platform and features mutations of L234A, L235A, and D265S in the constant region to abolish interaction with Fc receptors. Heterodimerization is enhanced using the Zymeworks Azymetric platform mutations. #mabs https://lnkd.in/e8SUjKHv

OmniAb to Participate in Two Investor Conferences in March https://lnkd.in/g54WMC7s

Take a different approach to your antibody discovery. Our chicken-based discovery platform, OmnidAb?, expresses heavy chain-only antibodies with human variable regions. As a result, discovery teams can achieve robust immune responses to conserved proteins and generate antibodies that: → Cover additional binding epitopes compared to standard antibodies → Bind with high affinity → Offer favorable developability metrics ? Read more about OmnidAb in our latest publication: https://hubs.la/Q034pDM30

Meet the OmniAb team at PepTalk, The Protein Science and Production Week. Swing by Booth 700 to explore our comprehensive suite of antibody discovery and development solutions and talk to our experts. Set up a time to chat: https://lnkd.in/gw9Y5jxZ #CHIPepTalk

OmniAb was invited to present in San Diego this weekend at PAG32, the largest animal genomics meeting in the world. Join Christine Vuong, PhD, for a presentation on genetic modifications to the chicken genome to obtain human antibodies for therapeutics. Learn more: https://lnkd.in/geJz5Y3y